TRK inhibitors such as LOXO-101, entrectinib, X396, AB-106, TL118 had remarkable and durable antitumor activities in patients (pts) with TRK fusion-positive cancers, regardless of age or tumor type. NTRK fusions are a rare molecular subtype in Chinese solid tumors. The NTRK gene fusions more commonly occurred in NSCLC (0.3%), CRC (0.4%) and BC (0.2%), and may occur without other targetable alterations such as EGFR, ALK, ROS1. The clinical evidence for responsiveness of NTRK fusions driven solid tumors provides an opportunity to personalize treatments and improve clinical outcomes for patients (pts).

almost 4 years ago

Clinical • Next-generation sequencing

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • TPM3 (Tropomyosin 3) • LMNA (Lamin A/C) • SQSTM1 (Sequestosome 1) • ESRP1 (Epithelial Splicing Regulatory Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK1 fusion • NTRK2 fusion • ETV6-NTRK3 fusion • TPM3-NTRK1 fusion • LMNA-NTRK1 fusion • NTRK fusion

Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Ensacove (ensartinib) • taletrectinib (AB-106) • Hamsa-1 (TL-118)